Form 8-K - Current report:
SEC Accession No. 0001104659-23-018997
Filing Date
2023-02-13
Accepted
2023-02-13 07:08:07
Documents
14
Period of Report
2023-02-10
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm236225d1_8k.htm   iXBRL 8-K 32626
2 EXHIBIT 3.1 tm236225d1_ex3-1.htm EX-3.1 8628
3 EXHIBIT 99.1 tm236225d1_ex99-1.htm EX-99.1 9853
  Complete submission text file 0001104659-23-018997.txt   234979

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apre-20230210.xsd EX-101.SCH 3024
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apre-20230210_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apre-20230210_pre.xml EX-101.PRE 22589
8 EXTRACTED XBRL INSTANCE DOCUMENT tm236225d1_8k_htm.xml XML 3719
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 23614656
SIC: 2834 Pharmaceutical Preparations